Immunotherapy and targeted drug before and after kidney cancer surgery
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of two drugs, cardenilimab and lenvatinib, given before and after surgery to remove kidney cancer. The goal is to see if this approach helps prevent the cancer from coming back. It is for people with early-stage (non-spread) clear cell kidney cancer who are healthy enough for surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with clear cell kidney cancer that has not spread and can be removed with surgery.
- You have not had any previous treatment for your cancer (like chemotherapy or immunotherapy).
- You are in generally good health (able to care for yourself, no major organ problems).
- You have not had certain other cancers, serious bleeding, or uncontrolled infections recently.
- If you are of childbearing age, you must agree to use birth control during the study and for 8 weeks after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—an immunotherapy (pembrolizumab) and two targeted therapies (belzutifan and lenvatinib)—given before surgery for high-risk kidney cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This trial tests whether giving pucotenlimab (an immunotherapy drug) with vorolanib (a targeted therapy) before surgery helps shrink clear cell kidney tumors and makes kidney-sparing surgery safer. It is for people with localized, non-metastatic disease where the tumor is difficult to remove with partial nephrectomy.
This trial tests whether giving immunotherapy before surgery can help people with advanced kidney cancer. The goal is to see if waiting on surgery and starting with medication that boosts the immune system is safe and effective.
This trial tests a new drug combination given before surgery for kidney cancer that is early stage but hard to operate on. The goal is to shrink the tumor and make surgery easier.
This trial tests if taking two drugs, belzutifan and pembrolizumab, before surgery can help shrink high-risk kidney cancer tumors and improve outcomes. It may be an option for people with locally advanced clear cell kidney cancer who are scheduled for nephrectomy.
This trial tests two drugs, alone or together, given before surgery to shrink kidney cancer tumors. It aims to see which approach works best for patients with intermediate- to high-risk clear cell renal cell carcinoma.
Hear when a new Resectable Clear Cell Carcinoma of the Kidney trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.